Cagrilintide: The Next Gen Peptide for Weight Loss and Satiety Hubmed Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet The combination of semaglutide and cagrilintide represents a more advanced approach to fat loss by targeting multiple hormonal pathways involved in appetite, satiety, and glucose regulation. Rather Once Weekly Combo Injection Cuts Weight by 20% Conexiant